As for ccRCC immune environment, activated CD8+ T lymphocytes (CD25+CD8+ T lymphocytes) (p = 0.0398) (Figure 2G) and central memory CD8+ T cells (CD45RO+CD62L+CD8+ T cells) (p = 0.0057) (Figure 2H) but effector memory CD8+ T cells (CD45RO+CD62L-CD8+ T lymphocytes) (p =0.77165) (Figure 2I) indicated worse prognosis of ccRCC patients. The gene discussed is SELL; the disease is nonpapillary renal cell carcinoma.